指南与共识妇科肿瘤

复发性卵巢癌系统治疗:ASCO 动态指南 2026.1.0 版

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
指南 / 共识 · J Clin Oncol · 2026-07-13

指南推荐铂敏感复发用铂类联合方案,铂耐药且 FRα 表达者强烈推荐 mirvetuximab soravtansine,手术方面证据不足以推荐二次减瘤或腹腔热灌注化疗。

要点

  • 铂敏感复发推荐铂类联合方案:PLD+卡铂、紫杉醇+卡铂或吉西他滨+卡铂,可加贝伐珠单抗及维持。
  • 铂耐药/难治且 FRα 表达者强烈推荐 mirvetuximab soravtansine,其他选项包括 PLD 单药等。
  • 证据不足以推荐二次减瘤或腹腔热灌注化疗,铂敏感且完全切除可能性高者可讨论二次减瘤。

核心结论

  • 复发性高级别浆液性和/或子宫内膜样上皮性卵巢癌的系统治疗应按铂敏感状态和 FRα 表达分层选择方案。

主要发现

  • 铂敏感复发推荐铂类联合方案:PLD+卡铂、紫杉醇+卡铂或吉西他滨+卡铂,可加贝伐珠单抗及维持。
  • 铂耐药/难治且 FRα 表达者强烈推荐 mirvetuximab soravtansine。
  • 其他推荐选项包括 PLD 单药、紫杉醇(每周或每 3 周)、贝伐珠单抗联合化疗或 relacorilant 联合白蛋白紫杉醇,吉西他滨单药为条件性替代。
  • 证据不足以推荐二次减瘤或腹腔热灌注化疗。

关键数值与推荐

  • 铂敏感复发:推荐 PLD+卡铂、紫杉醇+卡铂或吉西他滨+卡铂。
  • 铂耐药/难治且 FRα 表达:强烈推荐 mirvetuximab soravtansine。
  • 铂耐药/难治其他选项:PLD 单药、紫杉醇、贝伐珠单抗联合化疗、relacorilant 联合白蛋白紫杉醇;吉西他滨单药为条件性替代。
  • 二次减瘤:证据不足,铂敏感且完全切除可能性高者可讨论。

临床怎么用

  • 按铂敏感状态和 FRα 表达分层选择系统治疗方案。
  • 铂敏感复发优先考虑铂类联合方案,可联合贝伐珠单抗及维持。
  • 铂耐药/难治且 FRα 表达者优先考虑 mirvetuximab soravtansine。
  • 二次减瘤仅在不完全切除可能性高的铂敏感复发中讨论。
  • 治疗后监测和专科 survivorship 照护应个体化,可包括体检、生化检查和影像。

局限性

  • 证据不足以推荐二次减瘤或腹腔热灌注化疗。
  • 证据不足以推荐某一联合方案优于另一方案。
  • 动态指南不替代临床医生的独立专业判断,未考虑患者个体差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: [Box: see text]. PURPOSE: To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) experiencing recurrence. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eight hundred nineteen publications were identified in the literature search. After applying the eligibility criteria, 147 publications of randomized controlled trials and systematic reviews comprising the entire body of evidence remained, forming the evidentiary basis, of which 36 directly informed the guideline recommendations. RECOMMENDATIONS: For patients with recurrent platinum-sensitive EOC, clinicians should offer platinum-based combination regimens, specifically pegylated liposomal doxorubicin (PLD) plus carboplatin, paclitaxel plus carboplatin, or gemcitabine plus carboplatin. Bevacizumab may be added to a platinum-based doublet followed by bevacizumab maintenance. For patients who are not candidates for platinum-based therapy, clinicians may utilize recommendations for first-line treatment of patients with relapsed platinum-resistant disease. For patients with platinum-resistant or platinum-refractory EOC high-grade disease and validated folate receptor alpha (FRα) expression, mirvetuximab soravtansine is strongly recommended. Other recommended systemic options for this population include PLD monotherapy, paclitaxel (once weekly or once every 3 weeks), bevacizumab in combination with chemotherapy, or the combination of relacorilant and nab-paclitaxel; gemcitabine monotherapy remains a conditional alternative. Regarding surgical interventions, there is currently insufficient evidence to recommend secondary cytoreduction or hyperthermic intraperitoneal chemotherapy. Clinicians may discuss secondary cytoreduction for platinum-sensitive recurrences where complete gross resection is highly achievable. Post-treatment monitoring and specialty survivorship care should be offered on a case-by-case basis, potentially including physical exams, biochemical testing, and imaging. There is insufficient data to recommend one combination versus another.Additional information is available on the ASCO Publications website.Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in the Appendix (online only) for more.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. 2026. PMID: 42441925. doi:10.1200/JCO-26-01591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。